Company intelligence / Profile preview

Keylicon Biosciences

Boston, Massachusetts, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Keylicon has secured exclusive rights to a groundbreaking next-generation RNA technology developed at Boston University. This technology enables protein expression lasting over 30 days, can encode multiple proteins, and triggers a significantly lower immune response compared to conventional mRNA. In preclinical studies, it showed enhanced performance of a COVID-19 vaccine with efficacy at 100X lower doses than conventional mRNA[3][10].

Therapeutic areas: OncologyInfectious Diseases
Modalities: RNA-based therapeuticsself-amplifying RNA (saRNA)
Industry: Biotech

Partnerships

Boston University

Beyond the preview

Go deeper on Keylicon Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keylicon Biosciences.

Explore the full profile